新京报讯(记者王卡拉)对创新药而言,专利到期后势必将面临仿制药/生物类似药的围剿,原研药独占市场的辉煌时代将终结。作为新晋的全球“药王”,诺和诺德的司美格鲁肽在中国的核心化合物专利将于今年3月20日到期,此前已有多家本土药企发起了专利挑战。近日,中国最高人民法院就司美格鲁肽化合物专利相关知识产权作出有利判决,支持北京知识产权法院关于维持司美格鲁肽化合物专利有效的判决。 上述判决发布后,诺和诺德...
Source Link新京报讯(记者王卡拉)对创新药而言,专利到期后势必将面临仿制药/生物类似药的围剿,原研药独占市场的辉煌时代将终结。作为新晋的全球“药王”,诺和诺德的司美格鲁肽在中国的核心化合物专利将于今年3月20日到期,此前已有多家本土药企发起了专利挑战。近日,中国最高人民法院就司美格鲁肽化合物专利相关知识产权作出有利判决,支持北京知识产权法院关于维持司美格鲁肽化合物专利有效的判决。 上述判决发布后,诺和诺德...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.